Findings

What do systematic reviews say?

2,191 questions · 2,354 findings · 362 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 323 · 13.7%GRADE not reported 382 · 16.2%Very low 555 · 23.6%Low 597 · 25.4%Moderate 345 · 14.7%High 152 · 6.5%

Sitagliptin vs glipizide

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 552 participants
Low

Sitagliptin vs glipizide

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 552 participants
Low

Sitagliptin vs glipizide

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 551 participants
Moderate

SGLT2 inhibitors vs placebo

All cardiovascular death · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2788 participants
Low

Sitagliptin vs glipizide

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 551 participants
Very low

SGLT2 inhibitors vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1029 participants
Low

SGLT2 inhibitors vs placebo

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 848 participants
Moderate

SGLT2 inhibitors vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3086 participants
Low

SGLT2 inhibitors vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 917 participants
Very low

DPP‐4 inhibitors vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 867 participants
Low

Intervention not reported

LDL‐cholesterol fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 595 participants
High

Intervention not reported

Total cholesterol fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
27 studies · 3943 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Intervention not reported

Triglycerides fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 259 participants
High

Intervention not reported

Triglycerides fluvastatin 20 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 7510 participants
High

Intervention not reported

Triglycerides fluvastatin 40 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
48 studies · 2646 participants
High

Intervention not reported

Triglycerides fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 3623 participants
High

Intervention not reported

CI: Confidence interval · participants with normal or abnormal lipid profiles

The review found no eligible studies for this question.

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Mean baseline values. · participants with normal or abnormal lipid profiles

1 finding from 1 review

Fluvastatin for lowering lipids 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported